Yvette Drew
BC Cancer Agency · 218 works · 6,284 citations · h-index 29
Top works
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- Homologous recombination deficiency and ovarian cancer
- First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
- Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice
- Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
- An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
- The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
- Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
- PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
- Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
- Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
- Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant Cancers
- DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
- Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)